Zentalis Pharmaceuticals Reports Full Year 2025 Financial Results and Operational Updates

On track for DENALI Part 2a dose confirmation in 1H 2026DENALI Part 2 trial topline readout expected by year end 2026; potential to support accelerated approvalOn track to initiate the ASPENOVA Phase 3, randomized, confirmatory trial in 1H 2026Expanding azenosertib potential in ovarian cancer with the ongoing MUIR Part 2 trial evaluating the combination of azenosertib and bevacizumab as maintenance therapy$245.9 million cash, cash equivalents and marketable securities balance as of December 31, 2025, with p ...